MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:SKNY)

0.4000 UNCHANGED
Streaming Delayed Price Updated: 10:07 AM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6
Open 0.4000
Bid (Size) 0.3800 (1,000)
Ask (Size) 0.3900 (4,000)
Prev. Close 0.4000
Today's Range 0.4000 - 0.4000
52wk Range 0.3500 - 2.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
From Lir Life Sciences Corp.
Via ACCESS Newswire
News headline image
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
From Lir Life Sciences Corp.
Via ACCESS Newswire

Performance

YTD
-79.5%
-79.5%
1 Month
+2.6%
+2.6%
3 Month
-17.5%
-17.5%
6 Month
-79.3%
-79.3%
1 Year
-67.2%
-67.2%

More News

Read More
News headline image
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Via ACCESS Newswire
News headline image
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
Via ACCESS Newswire
News headline image
LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
Via ACCESS Newswire
News headline image
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Via ACCESS Newswire
News headline image
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Via ACCESS Newswire
News headline image
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
Via ACCESS Newswire
News headline image
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
Via ACCESS Newswire
News headline image
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
Via ACCESS Newswire
News headline image
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Via ACCESS Newswire
News headline image
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
Via ACCESS Newswire
News headline image
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Via ACCESS Newswire
News headline image
Lir Life Sciences Announces Engagement for IR Services
Via ACCESS Newswire
News headline image
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.
Via ACCESS Newswire

Frequently Asked Questions

Is SKNY publicly traded?
Yes, SKNY is publicly traded.
What exchange does SKNY trade on?
SKNY trades on the Canadian Securities Exchange
What is the ticker symbol for SKNY?
The ticker symbol for SKNY is SKNY on the Canadian Securities Exchange
What is the current price of SKNY?
The current price of SKNY is 0.4000
When was SKNY last traded?
The last trade of SKNY was at 07/15/26 10:07 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story